Know Cancer

or
forgot password

Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin


N/A
18 Years
N/A
Not Enrolling
Both
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin


OBJECTIVES: I. Determine the patterns of tissue factor pathway inhibitor (TFPI) release
according to tumor type and type of anticoagulation (heparin or enoxaparin) in patients with
cancer. II. Determine the incidence of portacath clots and its correlation to TFPI
releasability in this patient population. III. Compare these anticoagulation drugs in terms
of releasability of TFPI in this patient population.

OUTLINE: This is a randomized study. Patients are stratified according to prior chemotherapy
within the past 3 weeks (yes vs no). Patients are randomized to one of two treatment arms.
Arm I: Patients receive a single dose of standard heparin subcutaneously (SQ) followed by
evaluation of tissue factor pathway inhibitor (TFPI) response at 5 and 10 minutes post
injection. Arm II: Patients receive a single dose of enoxaparin SQ followed by evaluation of
TFPI response as in arm I. Patients are followed monthly for 3 months.

PROJECTED ACCRUAL: A total of 20-200 patients will be accrued for this study over 6 months.

Inclusion Criteria


DISEASE CHARACTERISTICS: Histologically proven malignancy, including lymphomas No
leukemias

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
expectancy: Greater than 6 months Hematopoietic: Hemoglobin greater than 8.5 g/dL Platelet
count greater than 100,000/mm3 No history of heparin and/or low weight molecular heparin
induced thrombocytopenia No history of bleeding diathesis Hepatic: No history of
coagulation factor deficiency No hepatic encephalopathy No hepatic failure No cirrhosis No
hemophilia Renal: Creatinine less than 2.5 mg/dL (no greater than upper limit of normal
for diabetes mellitus) Cardiovascular: No New York Heart Association class III or IV heart
disease No congestive heart failure No uncontrolled hypertension (i.e., systolic blood
pressure at least 180 mmHg and diastolic blood pressure at least 110 mmHg) No endocarditis
No hemorrhagic stroke No prior or concurrent deep vein thrombosis Pulmonary: No prior or
concurrent pulmonary embolus Other: No known allergy to enoxaparin or standard heparin No
known allergy to fish (e.g., protamine sulfate) or swine products No active ulcerative
disease or angiodysplasia of the gastrointestinal (GI) tract or active GI bleeding within
the past 6 months No other active significant medical illness or major failure of any
organ system No refusal of donor blood products secondary to religious or other reasons
Not pregnant or nursing

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Concurrent
chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Not specified Surgery:
At least 1 month since prior eye, spinal cord, or CNS surgery Other: At least 1 day since
prior heparin or enoxaparin At least 1 week since prior therapeutic coumadin (prior
prophylactic coumadin allowed) No other concurrent anticoagulants

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Hau C. Kwaan, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Veterans Affairs Medical Center - Lakeside Chicago

Authority:

United States: Federal Government

Study ID:

NU 96X2

NCT ID:

NCT00004875

Start Date:

July 1996

Completion Date:

March 1999

Related Keywords:

  • Lymphoma
  • Thromboembolism
  • Unspecified Adult Solid Tumor, Protocol Specific
  • stage I adult Hodgkin lymphoma
  • stage II adult Hodgkin lymphoma
  • stage III adult Hodgkin lymphoma
  • stage IV adult Hodgkin lymphoma
  • recurrent adult Hodgkin lymphoma
  • unspecified adult solid tumor, protocol specific
  • stage I grade 1 follicular lymphoma
  • stage I grade 2 follicular lymphoma
  • stage I grade 3 follicular lymphoma
  • stage I adult diffuse small cleaved cell lymphoma
  • stage I adult diffuse mixed cell lymphoma
  • stage I adult diffuse large cell lymphoma
  • stage I adult immunoblastic large cell lymphoma
  • stage I adult Burkitt lymphoma
  • stage III grade 1 follicular lymphoma
  • stage III grade 2 follicular lymphoma
  • stage III grade 3 follicular lymphoma
  • stage III adult diffuse small cleaved cell lymphoma
  • stage III adult diffuse mixed cell lymphoma
  • stage III adult diffuse large cell lymphoma
  • stage III adult immunoblastic large cell lymphoma
  • stage III adult Burkitt lymphoma
  • stage IV grade 1 follicular lymphoma
  • stage IV grade 2 follicular lymphoma
  • stage IV grade 3 follicular lymphoma
  • stage IV adult diffuse small cleaved cell lymphoma
  • stage IV adult diffuse mixed cell lymphoma
  • stage IV adult diffuse large cell lymphoma
  • stage IV adult immunoblastic large cell lymphoma
  • stage IV adult Burkitt lymphoma
  • recurrent grade 1 follicular lymphoma
  • recurrent grade 2 follicular lymphoma
  • recurrent grade 3 follicular lymphoma
  • recurrent adult diffuse small cleaved cell lymphoma
  • recurrent adult diffuse mixed cell lymphoma
  • recurrent adult diffuse large cell lymphoma
  • recurrent adult immunoblastic large cell lymphoma
  • recurrent adult Burkitt lymphoma
  • AIDS-related peripheral/systemic lymphoma
  • AIDS-related primary CNS lymphoma
  • stage I mantle cell lymphoma
  • contiguous stage II grade 1 follicular lymphoma
  • contiguous stage II grade 2 follicular lymphoma
  • contiguous stage II grade 3 follicular lymphoma
  • contiguous stage II adult diffuse small cleaved cell lymphoma
  • contiguous stage II mantle cell lymphoma
  • contiguous stage II adult diffuse mixed cell lymphoma
  • contiguous stage II adult immunoblastic large cell lymphoma
  • contiguous stage II adult diffuse large cell lymphoma
  • contiguous stage II adult Burkitt lymphoma
  • noncontiguous stage II grade 1 follicular lymphoma
  • noncontiguous stage II grade 2 follicular lymphoma
  • noncontiguous stage II grade 3 follicular lymphoma
  • noncontiguous stage II adult diffuse small cleaved cell lymphoma
  • noncontiguous stage II mantle cell lymphoma
  • noncontiguous stage II adult diffuse mixed cell lymphoma
  • noncontiguous stage II adult immunoblastic large cell lymphoma
  • noncontiguous stage II adult diffuse large cell lymphoma
  • noncontiguous stage II adult Burkitt lymphoma
  • stage III mantle cell lymphoma
  • stage IV mantle cell lymphoma
  • recurrent mantle cell lymphoma
  • angioimmunoblastic T-cell lymphoma
  • anaplastic large cell lymphoma
  • thromboembolism
  • noncontiguous stage II small lymphocytic lymphoma
  • noncontiguous stage II marginal zone lymphoma
  • recurrent marginal zone lymphoma
  • recurrent small lymphocytic lymphoma
  • stage I marginal zone lymphoma
  • stage I small lymphocytic lymphoma
  • stage III small lymphocytic lymphoma
  • stage III marginal zone lymphoma
  • stage IV small lymphocytic lymphoma
  • stage IV marginal zone lymphoma
  • contiguous stage II marginal zone lymphoma
  • contiguous stage II small lymphocytic lymphoma
  • extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  • nodal marginal zone B-cell lymphoma
  • splenic marginal zone lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Thromboembolism
  • Lymphoma, Large-Cell, Immunoblastic

Name

Location

Veterans Affairs Medical Center - Chicago (Lakeside)Chicago, Illinois  60611
Evanston Northwestern Health CareEvanston, Illinois  60201